NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and ...
Harrow, Inc. is an ophthalmology company with strong revenue growth, ambitious targets, and a diverse product portfolio including Vevye and Iheezo. HROW targets $280M in 2025 revenue and >$250M per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results